

BIOCON GROUP

F A C T S H E E T

March - 2014

YTD FY 2014 vs. YTD FY 2013

Q4 FY 2014 vs. Q4 FY 2013

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET	(Rs. Crores)	
	March 31, 2014	March 31, 2013
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,927	2,595
	3,027	2,695
Minority interest	82	65
Non-current liabilities		
(a) Long-term borrowings	606	164
(b) Deferred tax liability (net)	45	41
(c) Other long-term liabilities	603	424
(d) Long-term provisions	8	4
	1,262	633
Current liabilities		
(a) Short-term borrowings	244	85
(b) Trade payables	347	345
(c) Other current liabilities	612	347
(d) Short-term provisions	177	246
	1,380	1,023
TOTAL	5,751	4,416
ASSETS		
Non-current assets		
(a) Fixed assets	2,719	1,811
(b) Goodwill	12	12
(c) Non-current investments	65	64
(d) Long term loans and advances	269	248
(e) Other non-current assets	47	41
	3,112	2,176
Current assets		
(a) Current Investments	700	522
(b) Inventories	377	398
(c) Trade receivables	600	510
(d) Cash and cash equivalents	804	673
(e) Short term loans and advances	82	81
(f) Other current assets	76	56
	2,639	2,240
TOTAL	5,751	4,416

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Crores)

Particulars	FY 14	FY 13	Variance
INCOME			
Biopharmaceuticals	2,138	1,871	14%
Biopharma *	1,747	1,524	15%
Branded formulations - India	391	347	13%
Contract research	715	557	28%
Total Sales	2,853	2,428	18%
Other income	80	110	-27%
Total Revenue	2,933	2,538	16%
EXPENDITURE			
Material & Power costs	1,348	1,187	14%
Staff costs	428	358	20%
Research & Development **	131	164	-20%
Other expenses	283	233	21%
Manufacturing, staff & other expenses	2,190	1,942	
EBITDA	743	596	25%
Interest & Finance charges	2	8	
Depreciation & Amortisation	203	179	13%
PBT BEFORE EXCEPTIONAL ITEM	538	409	32%
Exceptional Item, Net		202	
PBT	538	611	-12%
Taxes	107	98	9%
NET PROFIT BEFORE MINORITY INTEREST	431	513	-16%
Minority interest	17	4	
NET PROFIT FOR THE PERIOD	414	509	-19%
EPS Rs.	20.7	25.4	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	15	25	
** Gross Research & Development expenses	152	198	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 14	Q4 FY 13	Variance
INCOME			
Biopharmaceuticals	535	464	15%
Biopharma *	442	379	17%
Branded formulations - India	93	85	9%
Contract research	188	166	13%
Total Sales	723	630	15%
Other income	23	19	21%
TOTAL REVENUE	746	649	15%
EXPENDITURE			
Material & Power costs	332	310	7%
Staff costs	112	99	13%
Research & Development **	29	43	-33%
Other expenses	80	73	10%
Manufacturing, staff & other expenses	553	525	
EBITDA	193	124	56%
Interest & Finance charges	1	1	
Depreciation & Amortisation	54	46	17%
PBT BEFORE EXCEPTIONAL ITEM	138	77	79%
Exceptional Item, Net		202	
PBT	138	279	-51%
Taxes	19	28	-32%
NET PROFIT BEFORE MINORITY INTEREST	119	251	-53%
Minority interest	6	2	
NET PROFIT FOR THE PERIOD	113	249	-55%
EPS Rs.	5.7	12.4	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	-	2	
** Gross Research & Development expenses	38	49	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 14	Q3 FY 14	Variance
INCOME			
Biopharmaceuticals	535	517	3%
Biopharma *	442	418	6%
Branded formulations - India	93	99	-6%
Contract research	188	183	3%
Total Sales	723	700	3%
Other income	23	19	21%
TOTAL REVENUE	746	719	4%
EXPENDITURE			
Material & Power costs	332	338	-2%
Staff costs	112	107	5%
Research & Development **	29	20	45%
Other expenses	80	67	19%
Manufacturing, staff & other expenses	553	532	
EBITDA	193	187	3%
Interest & Finance charges	1	-	
Depreciation & Amortisation	54	51	5%
PBT	138	136	2%
Taxes	19	26	
NET PROFIT BEFORE MINORITY INTEREST	119	110	9%
Minority interest	6	5	20%
NET PROFIT FOR THE PERIOD	113	105	8%
EPS Rs.	5.7	5.2	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharma Income includes:			
Licensing Income	-	4	
** Gross Research & Development expenses	38	23	